News Release
  January 8, 2013

CONTACT:

Holly Auer

215-349-5659
holly.auer@uphs.upenn.edu

Perelman School of Medicine


This announcement is available online at
http://www.uphs.upenn.edu/news/News_Releases/2013/01/ethics/

Penn Medicine Launches Nation's First Program for the Study of Ethical and Policy Issues in Neurodegenerative Diseases

PHILADELPHIA — The Perelman School of Medicine and the department of Medical Ethics and Health Policy at the University of Pennsylvania announce the creation of the Penn Neurodegenerative Disease Ethics and Policy Program. The new program will support research, education and training to identify and address the ethical and policy implications of advances in the diagnosis and treatment of neurodegenerative diseases, and work toward forming best practices for how these advances can be successfully translated into clinical practice.

“This first-of-its kind program positions Penn to be the national leader in an emerging area of neuroethics,” says Ezekiel Emanuel, MD, PhD, chair of the department of Medical Ethics and Health Policy. “It comes at a critical time in research and care. The millions of patients disabled by devastating neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, as well as their families, clinicians and policymakers, face notable ethical and policy challenges related to losses of function and decision-making capacity. In addition, progress in biomarkers that promise early, even pre-clinical, diagnosis and treatment is creating new ethical challenges.”

With support from the Provost’s Office, the MetLife Foundation, the Michael J. Fox Foundation and the Robert Wood Johnson Foundation, the program will examine the ethical, legal and social impact of neurodegenerative diseases; develop best practices and guidelines for biomarker testing in clinical trials and clinical care; and examine the value of biomarker-based diagnostics and therapeutics. The program will also create “Making sense of Alzheimer’s Disease,” a web-based resource to educate patients, families and clinicians about these issues.

Jason Karlawish, MD, professor of Medicine, Medical Ethics and Health Policy, will serve as the program’s inaugural director. Karlawish is the Associate Director of the Penn Memory Center and an international leader in the neuroethics of aging. His research has developed novel instruments to assess decisional capacity, examined the ethics and value Alzheimer’s disease clinical trial designs and diagnostics, and addressed voting rights for older adults with cognitive impairment.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.